Mimoun Azzouz, PhD
Chair Translational Neuroscience University of Sheffield, UK
-
Mimoun Azzouz, PhD
Chair Translational Neuroscience University of Sheffield, UK
-
Michael Fossel, MD, PhD
Founder, President
-
Peter Rayson
Founder, Chief Executive Officer
-
Mark Hodges
Chief Operating Officer (COO)
-
Russell Swerdlow, MD
Director of Alzheimer's Diease Center. Professor of Neurology, University of Kansas
-
Brian Kaspar, PhD
Center for Gene Therapy, Nationwide Children's Hospital Ohio
-
Suzanne Hendrix, PhD
President, Pentara Corporation Salt Lake City, Utah
-
Joseph Araujo, PhD
CEO and President, InterVivo Solutions
-
Zaven Khachaturian, PhD
Editor-in-Chief, Alzheimer’s & Dementia President PAD2020
Professor Mimoun Azzouz, formerly Director of Neurobiology at Oxford BioMedica plc, is currently Chair of Translational Neuroscience at the University of Sheffield. Azzouz is also Deputy Head of Neurology Unit and Director of Research & Innovation at the Neuroscience Department. His track record of translational research productivity is characterised by publications in top ranking scientific journals, including Nature, Nature Medicine, Nature Neuroscience, and STM. Several inventions emerged from his research. One of his major achievements is his involvement in a gene therapy approach designed to achieve dopamine replacement in models of Parkinson’s disease. This strategy has yielded significant translational impact having entered into phase I/II human clinical trials since 2008. He is currently driving 2 clinical development programs through regulatory tox, GMP clinical manufacturing and regulatory bodies. He recently won top level EU ad hominem prestigious ERC Advanced Investigator (2011) and ERC Proof-of-Concept (2017) Awards. These awards are acknowledging his pre-eminence in European biomedical research. He is/has been advisor for companies and academic institutions. He is currently a member of scientific Panels/Boards for various funding bodies such as the Medical Research Council (DPFS MRC, UK), the French Muscular Dystrophy Association (AFM), the Health Research Board (HRB) of Ireland and the Neuroscience Panel, Germany. He has been recently named as Board member of the British Society for Gene and Cell Therapy.